ライフサイエンスコーパス: vitamin D3

1 se effects were increased by the presence of vitamin D3.

2 other gastroprotective agents combined with vitamin D3.

3 venous calcium gluconate, magnesium and oral vitamin D3.

4 idered to improve clinical responsiveness to vitamin D3.

5 on and placebo tablets also contained 600 IU vitamin D3.

6 winter compared with an equivalent amount of vitamin D3.

7 dults in winter than an equivalent amount of vitamin D3.

8 nd thus must rely on cutaneous production of vitamin D3.

9 potentially toxic microbiome metabolite; and vitamin D3.

10 in D pathway genes on response to adjunctive vitamin D3.

11 o simvastatin 20 mg tablets twice-daily plus vitamin D3 1,000 international units capsules twice-dail

12 ut to define the role of 1alpha,25-dihydroxy vitamin D3 (1,25D) in regulating functional responses of

13 shed values that suggest people make "ample" vitamin D3 (~ 1,000 IU/day) from their "casual," or ever

14 The vitamin D metabolites (25-hydroxy vitamin D3, 1, 25-dihydroxy vitamin D3 and 24, 25-dihydr

15 High doses of the active form of vitamin D3, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], prev

16 ,25-dihydroxycholecalciferol (1,25-dihydroxy-vitamin D3; 1,25-VitD3) in the cardiovascular system is

17 Oral vitamin D3 (100,000 IU once, then 4000 IU/d for 28 weeks

18 Daily oral supplementation with vitamin D3 (1000 IU) or calcium carbonate (1200 mg eleme

19 Daily supplementation with vitamin D3 (1000 IU), calcium (1200 mg), or both after r

20 assigned 2259 participants to receive daily vitamin D3 (1000 IU), calcium as carbonate (1200 mg), bo

21 group who received one dosage of daily oral vitamin D3 (1000 IU), or a group who received 2 dosages

22 Lamb contained 0.10mug vitamin D3/100g and 0.20mug 25OHD3/100g lean meat, while

23 ed that 1,25-vitamin D3-deficient 25-hydroxy-vitamin-D3-1alpha-hydroxylase knockout mice and 1,25-vit

24 for 7 days, and vitamin K2 (30 mg/kg) and/or vitamin D3 (2 mug/kg) were administered for 10 days in t

25 ompared with placebo, participants receiving vitamin D3 (200,000 international units) demonstrated re

26 a group who received 2 dosages of daily oral vitamin D3 (2000 IU).

27 Vitamin D3 (2400 IU/d; n = 315) or matching placebo tabl

28 DA measurement [concentration of vitamin D2, vitamin D3, 25(OH)D2, and 25(OH)D3] at 2 wk and 2 mo pos

29 metabolites lacking a 1alpha-hydroxyl group (vitamin D3, 25-hydroxyvitamin D3, and 24R,25-dihydroxyvi

30 rations >10 and <60 ng/mL were randomized to Vitamin D3 2500 IU or placebo, daily for 4 months.

31 e also analyzed along with plasma 25-hydroxy vitamin D3 (25D) detection.

32 ine the content of vitamin D3 and 25-hydroxy-vitamin D3 (25OHD3), lamb and beef were analysed from 34

33 l, we investigated the effect of long-acting vitamin D3 (400,000 IU) on sputum neutrophils and eosino

34 In healthy volunteers, supplementation of vitamin D3 (4000 IU cholecalciferol per day) increased t

35 and were randomly assigned to receive either vitamin D3 (4000 IU/d) or placebo as part of their stand

36 healthy; 2) periodontitis; 3) SRP; 4) SRP + vitamin D3; 5) SRP + vitamin K2; and 6) SRP + vitamins K

37 igned to receive monthly treatment with oral vitamin D3 (50,000 IU; n = 209) or an identical placebo

38 jects were randomly assigned to receive oral vitamin D3 [50,000 IUs (1.25 mg) thrice weekly for 8 wk

39 = 85), and randomized within those groups to vitamin D3, 50 000 IU (n = 102) or placebo (n = 101), ad

40 tary administration of high doses of regular vitamin D3 (800 IU/day) during different periods of life

41 Adjunctive vitamin D3 accelerated sputum culture conversion in pati

42 mulating hormone, free thyroxine, 25-hydroxy vitamin D3, active smoking status and body mass index we

43 A major limitation of exogenous vitamin D3 administration for the treatment of prostate

44 ctivation, and clearance was associated with vitamin D3 administration.

45 100g lean meat, while beef contained 0.12mug vitamin D3 and 0.27mug 25OHD3/100g (lean meat).

46 creatinine, parathyroid hormone, 25 hydroxy vitamin D3 and 1, 25 dihydroxy vitamin D3 were measured

47 ffect of 1,25-vitamin D3 deficiency and 1,25-vitamin D3 and 1,25-vitamin D2 repletion on proteinuria

48 daily supplementation with 400 IU or less of vitamin D3 and 1000 mg or less of calcium for the primar

49 in D3 + calcium group) received 2000 IU/d of vitamin D3 and 1500 mg/d of calcium; the placebo group r

50 ites (25-hydroxy vitamin D3, 1, 25-dihydroxy vitamin D3 and 24, 25-dihydroxy vitamin D3) were measure

51 To determine the content of vitamin D3 and 25-hydroxy-vitamin D3 (25OHD3), lamb and

52 No difference between retention of vitamin D3 and 25-hydroxyvitamin D3 in eggs was shown.

53 We investigated the retention of vitamin D3 and 25-hydroxyvitamin D3 in eggs, vitamin D3

54 et and purchase date on the concentration of vitamin D3 and 25-hydroxyvitamin D3.

55 R- and 20S-isomers of 25-hydroxy-2-methylene-vitamin D3 and 3-desoxy-1alpha,25-dihydroxy-2-methylene-

56 D status and dose-response, we performed two vitamin D3 and calcium clinical supplementation trials i

57 D level of 32.8 ng/mL, supplementation with vitamin D3 and calcium compared with placebo did not res

58 To determine if dietary supplementation with vitamin D3 and calcium reduces the risk of cancer among

59 r with LPS and dexamethasone, vitamin D3, or vitamin D3 and dexamethasone instructed NK cells to secr

60 supplementation with greater than 400 IU of vitamin D3 and greater than 1000 mg of calcium for the p

61 cytokine-mobilized donor blood monocytes in vitamin D3 and IL-10, on renal allograft survival in a c

62 zation enhanced the ionisation efficiency of vitamin D3 and its isomers in UHPLC-MS/MS and improved t

63 Within the limitations of this study, vitamin D3 and K2 alone or in combination did not affect

64 m as evidenced by increased serum 1,25-(OH)2-vitamin D3 and parathyroid hormone levels, decreased ser

65 ilar median culture-conversion times between vitamin D3 and placebo groups [29 and 27 d, respectively

66 rates were also similar (84.0% and 82.1% for vitamin D3 and placebo, respectively; P = 0.99).

67 and pre-vitamin D3 takes place to form trans-vitamin D3 and tachysterol, respectively.

68 LDL-cholesterol concentrations between oral vitamin D3 and UVB groups (difference in median of oral

69 min D3 in eggs, vitamin D3 in margarine, and vitamin D3 and vitamin D2 in bread.

70 The two major forms of vitamin D, vitamin D3 and vitamin D2, are metabolized in the liver

71 The synergistic effects of vitamin D3 and vitamin K2 on bone loss prevention have b

72 This study evaluates the effects of vitamin D3 and vitamin K2 supplementation in conjunction

73 0 international units/kg diet, respectively) vitamin D3, and hippocampal-dependent learning and memor

74 Fibroblast growth factor-23, 1,25-(OH)2-vitamin D3, and insulin concentrations did not respond,

75 issected the basis for the resistance to the vitamin D3 antitumor properties and specifically examine

76 the literature as to whether vitamin D2 and vitamin D3 are equally effective in increasing and maint

77 While the antiinflammatory effects of vitamin D3 are well described, we found that, conversely

78 n 25(OH)D was 13.6 (11.6, 15.4) ng/mL in the vitamin D3 arm compared with -1.3 (-2.6, -0.3) ng/mL in

79 All women received 400 IU/d of vitamin D3 as part of usual pregnancy care.

80 Vitamin D3 at 3750 IU/d did not improve HOMA-IR compared

81 -activity relationship study for a series of vitamin D3-based (VD3) analogues that incorporate aromat

82 on in the 2 ethnic groups combined, both the vitamin D3 biscuit and the vitamin D3 juice groups showe

83 lation of immune pathway signaling with oral vitamin D3 but significant downregulation with UVB.Corre

84 rs was 0.042 (95% CI, 0.032 to 0.056) in the vitamin D3 + calcium group and 0.060 (95% CI, 0.048 to 0

85 cluded renal calculi (16 participants in the vitamin D3 + calcium group and 10 in the placebo group),

86 and elevated serum calcium levels (6 in the vitamin D3 + calcium group and 2 in the placebo group).

87 droxyvitamin D levels were 43.9 ng/mL in the vitamin D3 + calcium group and 31.6 ng/mL in the placebo

88 irmed in 109 participants, 45 (3.89%) in the vitamin D3 + calcium group and 64 (5.58%) in the placebo

89 The treatment group (vitamin D3 + calcium group) received 2000 IU/d of vitami

90 OH)2D3 locally, we hypothesized that dietary vitamin D3 can also prevent disease.

91 irst time that high doses of regular dietary vitamin D3 can safely prevent diabetes in NOD mice when

92 to receive either placebo or a high dose of vitamin D3 (cholecalciferol) one hour after experimental

93 ish safety and efficacy of high-dose 25 (OH) vitamin D3 (cholecalciferol) supplementation in patients

94 CYP24A1 may be a predictive marker of vitamin D3 clinical efficacy in patients with advanced p

95 maximum dose of 20kJ/m(2) produced 3.5-4mug vitamin D3/cm(2) pig skin.

96 We therefore investigated whether vitamin D3 (colecalciferol) supplementation would reduce

97 8 patients (28.6% [95% CI, 19.9%-38.6%]) for vitamin D3 compared with 47 deaths among 102 patients (4

98 Vitamin D3 compared with placebo did not affect time to

99 in D deficiency, administration of high-dose vitamin D3 compared with placebo did not reduce hospital

100 Results demonstrated a higher vitamin D3 concentration in free range (57.2+/-3.1mug/kg

101 endent associations between myopia and serum vitamin D3 concentrations nor variants in genes associat

102 in vitamin D metabolic pathway genes, serum vitamin D3 concentrations, and years of education.

103 Odds ratios (ORs) of UVB, serum vitamin D3 concentrations, vitamin D single-nucleotide p

104 This diabetes protection by vitamin D3 correlated with preserved pancreatic insulin

105 concentrations than is vitamin D2, and thus vitamin D3) could potentially become the preferred choic

106 nmol . L(-1) . mug intake(-1) for the 20-mug vitamin D3/d and 7- and 20-mug 25-hydroxyvitamin D3/d gr

107 olescents the efficacy and safety of 4000 IU vitamin D3/d and whether subsequent increased circulatin

108 5-hydroxyvitamin D3/d groups with the 20-mug vitamin D3/d group yielded conversion factors of 4.2 and

109 ts received 1000 mg elemental Ca with 400 IU vitamin D3/d or placebo (median follow-up: 6.5 y).

110 domly assigned to weight loss + 2000 IU oral vitamin D3/d or weight loss + daily placebo.

111 were assigned to 0 (placebo), 10, or 20 mug vitamin D3/d supplementation for 20 wk.

112 eceived active intervention (1 g Ca + 400 IU vitamin D3/d) in the Calcium/Vitamin D Trial.

113 nmol/L in the groups receiving 10 and 20 mug vitamin D3/d, respectively, and decreased by 24.1 +/- 1.

114 ndertook PRT 2 times/wk and received 1000 IU vitamin D3/d.

115 To investigate whether novel pathways of vitamin D3 (D3) and 7-dehydrocholesterol (7DHC) metaboli

116 stability of the beta-lactoglobulin (betalg)/vitamin D3 (D3) complex at 4 degrees C and upon exposure

117 Vitamin D3 (D3) was encapsulated within a water-soluble

118 In parathyroid hormone or 1alpha,25(OH)2-vitamin D3 (D3)-stimulated bone marrow cultures (BMC) fr

119 bitory via production of hedgehog-inhibiting vitamin D3 (D3).

120 total of 204 T2DM subjects received 2000 IU vitamin D3 daily for 12 months.

121 amin D3, or biscuit supplemented with 15 mug vitamin D3 daily for 12 wk.

122 Conversely, the measured bioaccessibility of vitamin D3 decreased in the following order: corn oil ap

123 The effect of 1,25-vitamin D3 deficiency and 1,25-vitamin D3 and 1,25-vitam

124 n impaired renal function also leads to 1,25-vitamin D3 deficiency as a result of reduced renal 1alph

125 This study demonstrates that 1,25-vitamin D3 deficiency directly leads to renal injury in

126 High doses induce vascular calcification; vitamin D3 deficiency, however, has been linked to cardi

127 Herein, we showed that 1,25-vitamin D3-deficient 25-hydroxy-vitamin-D3-1alpha-hydrox

128 erular and tubulointerstitial damage in 1,25-vitamin D3-deficient animals, thereby preserving and res

129 e podocyte was significantly altered in 1,25-vitamin D3-deficient animals.

130 D3-1alpha-hydroxylase knockout mice and 1,25-vitamin D3-deficient rats develop podocyte injury and re

131 placebo, participants using simvastatin plus vitamin D3 demonstrated a greater decrease in number of

132 Treatment with vitamin D3 did not alter the rate of first treatment fai

133 Vitamin D3 did not influence time to sputum culture conv

134 Vitamin D3 did not reduce the rate of first treatment fa

135 hibiting Hedgehog signaling, whereas dietary vitamin D3 does not.

136 beneficial effects were negated with higher vitamin D3 doses.

137 To protect vitamin D3 during cold storage and exposure to UV-light,

138 cts of Grisu(R) alone or in combination with vitamin D3 during oxidative stress or high acid expositi

139 y of maternal supplementation with 4400 IU/d vitamin D3 during the second and third trimesters of pre

140 The use of 2800 IU/d of vitamin D3 during the third trimester of pregnancy compa

141 that addition of 1,25D3, the active form of vitamin D3, during CD8(+) T-cell differentiation prevent

142 in which baseline 25(OH)D was accounted for, vitamin D3-egg and 25(OH)D3-egg groups were shown to hav

143 carrier oil type on the bioaccessibility of vitamin D3 encapsulated within oil-in-water nanoemulsion

144 in which status was expected to decline), 7 vitamin D3-enhanced eggs/wk, or seven 25(OH)D3-enhanced

145 Testing this hypothesis, we found vitamin D3 failed to inhibit EAE in female Ifng knockout

146 dose of 200 000 IU (5.0 mg) colecalciferol (vitamin D3) followed by monthly 100 000 IU (2.5 mg) cole

147 (4000 IU/d) versus low-dose (400 IU/d) oral vitamin D3 for 6 months.

148 e aimed to investigate whether vitamin D2 or vitamin D3 fortified in juice or food, at a relatively l

149 240 patients were randomly allocated to the vitamin D3 group (n=122) and placebo group (n=118).

150 e included in the final analysis (237 in the vitamin D3 group and 238 in the placebo group).

151 3 years of life in 47 children (16%) in the vitamin D3 group and 57 children (20%) in the control gr

152 crog/d [95% CI, 102.2-120.4 microg/d] in the vitamin D3 group vs 126.2 microg/d [95% CI, 117.2-135.3

153 tal malformations in 17 neonates (5%) in the vitamin D3 group vs 23 neonates (8%) in the control grou

154 e death was observed in 1 fetus (<1%) in the vitamin D3 group vs 3 fetuses (1%) in the control group

155 of RCTs indicated that supplementation with vitamin D3 had a significant and positive effect in the

156 Participants supplemented with vitamin D3 had increases in serum 25(OH)D concentrations

157 uring cold storage and exposure to UV-light, vitamin D3 has been entrapped in microspheres formed by

158 and 3-desoxy-1alpha,25-dihydroxy-2-methylene-vitamin D3 have been synthesized.

159 Moreover, the combination of Grisu(R) and vitamin D3 improves cell viability and decreases ROS pro

160 plementing inhaled corticosteroids with oral vitamin D3 improves outcomes in patients with asthma and

161 Oral vitamin D3 in an initial dose of 200000 IU, followed a m

162 24A1 RNAi enhanced the cytostatic effects of vitamin D3 in human prostate cancer cells.

163 to be 2.4 times more efficient in producing vitamin D3 in human skin than the sun in less than 1/60(

164 tuned to different wavelengths for producing vitamin D3 in human skin.

165 vitamin D3 and 25-hydroxyvitamin D3 in eggs, vitamin D3 in margarine, and vitamin D3 and vitamin D2 i

166 recommended in the recipe, the retention of vitamin D3 in rye bread at 69% was lower than the retent

167 young adults in Cape Town, supplemented with vitamin D3 in winter, to determine whether vitamin D sta

168 mediator production in vitro, as well as the vitamin D3-induced curtailment of PCA responses in WBB6F

169 Compelling evidence suggests that vitamin D3 insufficiency may contribute causally to mult

170 Because immune cells themselves can convert vitamin D3 into 1,25(OH)2D3 locally, we hypothesized tha

171 By inducing SDF1, vitamin D3 is a novel approach to promote vascular repai

172 This study was planned to assess whether vitamin D3 is a protective factor against acid injury an

173 Vitamin D3 is generated secondary to exposure to ultravi

174 Cholecalciferol or vitamin D3 is known to isomerise under various condition

175 This meta-analysis indicates that vitamin D3 is more efficacious at raising serum 25(OH)D

176 ,25(OH)2D3], the biologically active form of vitamin D3, is a pleiotropic hormone that exerts its eff

177 at calcitriol, the hormonally active form of vitamin D3, is an excellent candidate for transmission o

178 ls-Alder reaction confirmed the formation of vitamin D3 isomerisation products.

179 ombined, both the vitamin D3 biscuit and the vitamin D3 juice groups showed a significantly greater a

180 participants with significantly higher serum vitamin D3 levels after treatment (P = 0.007) demonstrat

181 Inclusion of 25-hydroxy vitamin D3 levels did not substantially affect the posit

182 In contrast, participants with lower serum vitamin D3 levels had significant expression of proinfla

183 ts suggest that Grisu(R) in combination with vitamin D3 may exert a gastroprotective effect to mainta

184 Vitamin D3 may therefore be a preferential form to optim

185 lopment was associated with dysregulation of vitamin D3 metabolism at all stages and plasma 25-hydrox

186 Cyp24a1 gene expression, implying equivalent vitamin D3 metabolism in the CNS.

187 table and protease resistant and include the vitamin D3 metabolite 1alpha,25-dihydroxyvitamin D3 and

188 failure, where concentrations of the active vitamin D3 metabolite, 1alpha,25-dihydroxyvitamin D3 (1a

189 The vitamin D3 metabolite, 20S,23S-dihydroxyvitamin D3, was

190 n D3 [1,20S(OH)2D3], a natural and bioactive vitamin D3 metabolite, was chemically synthesized for th

191 Bioactive vitamin D3 metabolites 20S,24S-dihydroxyvitamin D3 [20S,

192 We sought to assess whether the vitamin D3 metabolites 25OHD3 and 1alpha,25(OH)2D3 can r

193 Epidermal-derived vitamin D3 metabolites and PGs provide an essential cue

194 Vitamin D3 metabolites lacking a 1alpha-hydroxyl group (

195 Furthermore, epicutaneously applied vitamin D3 metabolites significantly reduced the magnitu

196 ough CYP27B1 activity and that both of these vitamin D3 metabolites suppressed IgE-induced mast cell-

197 and UVB groups (difference in median of oral vitamin D3 minus that of UVB: 1.5 mg/dL; 95% CI: -5.0, 7

198 e four biweekly doses of 3.5 mg (140,000 IU) vitamin D3 (n = 190) or placebo (n = 200) during intensi

199 ncy (</=20 ng/mL) assigned to receive either vitamin D3 (n = 249) or a placebo (n = 243).

200 5110 participants were randomized to receive vitamin D3 (n = 2558) or placebo (n = 2552).

201 enishment between subjects who received oral vitamin D3 (n = 60) and those who received narrow-band U

202 quate outdoor UVB exposures to satisfy their vitamin D3 needs all year, except some Caucasians during

203 relative potency of 25-hydroxyvitamin D3 to vitamin D3 needs to be better defined so that food-compo

204 anation for the anti-inflammatory effects of vitamin D3 on mast cell function by demonstrating that m

205 To determine the effect of high-dose vitamin D3 on response to antimicrobial therapy for PTB

206 ectly compared the effects of vitamin D2 and vitamin D3 on serum 25(OH)D concentrations in humans.

207 Supplementation with 1,25-vitamin D3 or 1,25-vitamin D2 prevented podocyte effacem

208 B1, CYP24A1, and CASR) modify the effects of vitamin D3 or calcium supplementation on colorectal aden

209 to receive six 2-monthly oral doses of 3 mg vitamin D3 or placebo over 1 year in a 1:1 ratio using c

210 Vitamin D3 or placebo was given orally or via nasogastri

211 eceive 1000 mg/d of calcium plus 400 IU/d of vitamin D3 or placebo.

212 feeding hens at the maximum concentration of vitamin D3 or serum 25-hydroxyvitamin D [25(OH)D3] lawfu

213 ecting vitamin D deficiency with either oral vitamin D3 or UVB does not improve the lipid profile.

214 -controlled, randomised controlled trials of vitamin D3 or vitamin D2 supplementation in people with

215 50 y (n = 56) who consumed a placebo, 20 mug vitamin D3, or 7 or 20 mug 25-hydroxyvitamin D3 daily th

216 g vitamin D2, juice supplemented with 15 mug vitamin D3, or biscuit supplemented with 15 mug vitamin

217 C treated either with LPS and dexamethasone, vitamin D3, or vitamin D3 and dexamethasone instructed N

218 ed with higher deseasonalised 1,25-dihydroxy vitamin D3 (p=0.003) levels and a trend was found for de

219 rend was found for deseasonalised 25-hydroxy vitamin D3 (p=0.014).

220 Latitude had no effect on the vitamin D3 (P=0.21) or 25OHD3 (P=0.29) content of lean b

221 With vitamin D3, plasma 25(OH)D concentrations peaked at appr

222 patients were randomly assigned (79 received vitamin D3 plus calcium and 86 received placebo).

223 evels of 25-hydroxyvitamin D3 increased with vitamin D3 plus calcium but not with placebo: Median cha

224 decline in total hip BMD was smaller in the vitamin D3 plus calcium group than in the placebo group:

225 Vitamin D3 plus calcium supplementation mitigates the BM

226 Makarova et al. now show that vitamin D3 produced in the skin by UVR protects against

227 Vitamin D3 produced was independent on the combination o

228 elength of 296nm was found to be optimal for vitamin D3 production.

229 y during winter because of negligible dermal vitamin D3 production.

230 showed different properties with respect to vitamin D3 receptor activation, anti-inflammatory activi

231 of these products were compared in terms of vitamin D3 receptor activation, anti-inflammatory, and a

232 emonstrated that retinoic acid (RAR-RXR) and vitamin D3 receptors (VDR-RXR) heterodimers recruit only

233 A high-dose vitamin D3 regimen safely corrected vitamin D deficiency

234 te cell line by differentiation with PMA and vitamin D3, respectively.

235 Supplementation of mothers with 4400 IU of vitamin D3 resulted in an enhanced broad-spectrum proinf

236 Vitamin D3 significantly promoted RANKL expression in AB

237 ) were administered for 10 days in the SRP + vitamin D3, SRP + vitamin K2, and SRP + vitamins K2 and

238 Participants were allocated to 1 year of vitamin D3 supplementation (4,000 IU [100 mug] daily) or

239 High-dosage oral vitamin D3 supplementation attenuated HIV-1 replication,

240 In youth on TDF, vitamin D3 supplementation decreased PTH, regardless of

241 One year of high-dose vitamin D3 supplementation did not improve 6-min walk di

242 One year of 100 mug daily vitamin D3 supplementation does not improve 6-min walk d

243 Vitamin D3 supplementation during weight loss did not in

244 Our findings suggest that benefits from vitamin D3 supplementation for the prevention of advance

245 We determined whether adjunctive high-dose vitamin D3 supplementation improves outcomes in individu

246 d, double-blind, placebo-controlled trial of vitamin D3 supplementation in adults with COPD in 60 gen

247 ngs do not support a strategy of therapeutic vitamin D3 supplementation in patients with symptomatic

248 aimed to investigate the in vivo sequelae of vitamin D3 supplementation in systemic Candida infection

249 ong individuals with 1 or 2 G alleles (74%), vitamin D3 supplementation increased risk by 41% (RR, 1.

250 Vitamin D3 supplementation may therefore be a useful adj

251 The effect of vitamin D3 supplementation on advanced adenomas, but not

252 Vitamin D3 supplementation protected against moderate or

253 mong individuals with the AA genotype (26%), vitamin D3 supplementation reduced risk by 64% (RR, 0.36

254 Vitamin D3 supplementation was not associated with the r

255 a beneficial association of 1 g Ca + 400 IU vitamin D3 supplementation with lung cancer.

256 We compared 12 mo of vitamin D3 supplementation with placebo on weight, body

257 in tumor volume when mice were subjected to vitamin D3 supplementation.

258 centrations compared with the effect of oral vitamin D3 supplementation.We performed a randomized cli

259 were randomly assigned to receive milk-based vitamin D3 supplements that provided 2 (placebo), 10, or

260 andomly assigned to receive 0, 10, or 20 mug vitamin D3 supplements/d for 20 wk during winter.

261 ly assigned to receive oral cholecalciferol (vitamin D3) supplements of 400 IU/d (n=39), 800 IU/d (n=

262 Vitamin D3 supports 1,25-dihydroxyvitamin D3 (1,25-[OH]2

263 We measured the extent of vitamin D3 suppression of IgE-mediated mast cell degranu

264 somerisation of both cholecalciferol and pre-vitamin D3 takes place to form trans-vitamin D3 and tach

265 nificantly higher (P<0.01) concentrations of vitamin D3 than fat from the 41 degrees S group of cattl

266 ids; specialized proresolving mediators; and vitamin D3 that have proven immune effects and emerging

267 Vitamin D3, the active form of vitamin D, may counteract

268 o receive an initial dose of 200,000 IU oral vitamin D3, then 200,000 IU 1 month later, then 100,000

269 Vitamin D3 therefore presents as a low-cost supplementat

270 Vitamin D3 thermally and reversibly transforms to pre-vi

271 )2D3), the biologically active metabolite of vitamin D3 To further investigate the mechanism of this

272 Terminal activation of vitamin D3 to its hormonal form, 1alpha,25-dihydroxyvita

273 sphate-treated VSMCs and aortic rings and in vitamin D3-treated mice.

274 Moreover, vitamin D3 treatment decreased interferon-gamma-positive

275 vitamin D2 weekly plus 200 units of calcium/vitamin D3 twice daily.

276 3 thermally and reversibly transforms to pre-vitamin D3 type isomers.

277 Vitamin D3, used as a model nutraceutical, was successfu

278 Vitamin D3 (VD), a hydrophobic micronutrient, was succes

279 a(ep-/-)) or a topical application of active vitamin D3 (VD3) and/or all-trans retinoic acid (RA) on

280 We sought to determine the effect of CS on vitamin D3 (VD3) levels, conversion, and regulation of C

281 ntify coeluted vitamin E succinate (VES) and vitamin D3 (VD3).

282 For this study, model drug (vitamin D3, VD3)-loaded PLGA nano- and microparticles (N

283 calciferol (vitamin D2) and cholecalciferol (vitamin D3) (vitamin D) and 25-hydroxivitamin D2 plus D3

284 re is currently widespread interest in using vitamin D3 (VitD3) as an adjunct therapy for TB because

285 study groups: 20.1 days (IQR, 12.9-39.1) for vitamin D3 vs 19.0 days (IQR, 11.6-33.8) for placebo.

286 tween groups (20.1 days [IQR, 11.1-33.3] for vitamin D3 vs 19.3 days [IQR, 11.1-34.9] for placebo; P

287 during 28 weeks (28% [95% CI, 21%-34%] with vitamin D3 vs 29% [95% CI, 23%-35%] with placebo; adjust

288 l mortality: 28.3% [95% CI, 22.6%-34.5%] for vitamin D3 vs 35.3% [95% CI, 29.2%-41.7%] for placebo; h

289 h mortality: 35.0% [95% CI, 29.0%-41.5%] for vitamin D3 vs 42.9% [95% CI, 36.5%-49.4%] for placebo; H

290 h mortality (34.7% [95% CI, 25.4%-45.0%] for vitamin D3 vs 50.0% [95% CI, 39.9%-60.1%] for placebo; H

291 in D levels increased by 15.7 (9.3) ng/mL on vitamin D3 vs. -0.2 (6.1) ng/mL on placebo (p<0.001).

292 The combined effect of Grisu(R) and vitamin D3 was found more effective in counteracting the

293 s relevant to food-fortification strategies, vitamin D3 was more effective than vitamin D2 in increas

294 Prespecified subgroup analysis showed that vitamin D3 was protective against moderate or severe exa

295 h detrimental (skin cancers) and beneficial (vitamin D3) ways.

296 h 4400 IU/d (n = 26) or 400 IU/d (n = 25) of vitamin D3 were analyzed for immune cell composition by

297 e, 25 hydroxy vitamin D3 and 1, 25 dihydroxy vitamin D3 were measured in 47 children with IBD during

298 ions, and oxidation, on the isomerisation of vitamin D3 were studied using HPLC-DAD and UHPLC-MS/MS.

299 25-dihydroxy vitamin D3 and 24, 25-dihydroxy vitamin D3) were measured using mass spectrometry.

300 mpared, there was a significant response for vitamin D3 when given as a bolus dose (P = 0.0002) compa

301 We estimated how much vitamin D3 young Americans (n = ~ 2,000) produce from th